116 related articles for article (PubMed ID: 21417860)
1. Antiangiogenic therapies: is VEGF-A inhibition alone enough?
Gordon MS
Expert Rev Anticancer Ther; 2011 Mar; 11(3):485-96. PubMed ID: 21417860
[TBL] [Abstract][Full Text] [Related]
2. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
4. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
5. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
6. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Ellis LM; Hicklin DJ
Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
[TBL] [Abstract][Full Text] [Related]
7. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to vascular endothelial growth factor blockade.
Abdullah SE; Perez-Soler R
Cancer; 2012 Jul; 118(14):3455-67. PubMed ID: 22086782
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
Limaverde-Sousa G; Sternberg C; Ferreira CG
Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
[TBL] [Abstract][Full Text] [Related]
11. [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
Taillade L; Alexandre I; Billemont B; Meric JB; Sultan-Amar V; Rixe O
Bull Cancer; 2009; 96 Suppl 1():S45-55. PubMed ID: 19433373
[TBL] [Abstract][Full Text] [Related]
12. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for cancer: an update.
Shojaei F; Ferrara N
Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
[TBL] [Abstract][Full Text] [Related]
14. Novel antiangiogenic therapies for renal cell cancer.
Gordon MS
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
[TBL] [Abstract][Full Text] [Related]
15. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?
Hlushchuk R; Makanya AN; Djonov V
Int J Dev Biol; 2011; 55(4-5):563-7. PubMed ID: 21858777
[TBL] [Abstract][Full Text] [Related]
16. [Antiangiogenic pathways in the future].
Neuzillet Y; Delbado C
Prog Urol; 2011 Mar; 21 Suppl 2():S13-5. PubMed ID: 21397821
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
18. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
20. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
